Ardena Expands Bioanalytical Services with New Lab in Oss, Netherlands

• Ardena announces new bioanalytical lab in Oss, Netherlands, expanding its CDMO capabilities.

• The 3,000+ sqft facility will offer advanced bioanalytical services, operational by Q1 2025.

Ardena, a pharmaceutical contract development and manufacturing organisation (CDMO), has announced an expansion of its bioanalytical services in the Netherlands. The investment includes a 3,000-square-foot lab at Pivot Park in Oss, expected to be operational by Q1 2025, alongside upgrades to the Bioanalytical Center of Excellence in Assen. This expansion aims to address the rising demand for comprehensive bioanalytical services and to enhance Ardena’s capacity for both small and large molecule analysis.

The new Oss facility will feature advanced testing capabilities, including LC-MS/MS, fluorometric detection assays, and an ELISA-based Gyrolab automated platform. Meanwhile, the Assen site enhancements will increase capacity for immunochemistry, flow cytometry, and qPCR analysis. Ardena is also implementing Hamilton automated systems in Assen to streamline its processes and better meet evolving bioanalytical needs.

“This expansion allows us to quickly scale our operations, leverage an additional pool of talented professionals, and bring enhanced efficiency and value to our clients, from discovery to late stage clinical phases,” said Jeremie Trochu, CEO of Ardena. These expanded capabilities will support a wide range of clients, from biotech innovators to large pharmaceutical companies, across various drug development stages.

The addition of the Oss lab will provide Ardena’s clients with greater flexibility and faster turnaround times, complementing existing services in Assen. Ardena’s expanded bioanalytical offerings include expertise in small molecules, therapeutic peptides and proteins, antibodies, antibody-drug conjugates, nanoparticles, oligonucleotides, mRNA, and cell and gene therapies.